German Biotech iDEL Secures $9.7M to Advance Cancer Drug Platform

Jan de Vries · 2026-03-17

Here's some exciting news from the world of cancer research. A German biotech company called iDEL Therapeutics just announced a major milestone. They've closed a Seed financing round worth about $9.7 million. That's a significant vote of confidence for their mission: developing a new pipeline of cancer therapeutics designed to be delivered straight into the heart of tumor cells. This isn't just about one company, though. It's part of a bigger story happening across Europe right now. There's a real surge of investment flowing into innovative oncology treatments. We're talking about new ways to fight cancer that go beyond traditional chemotherapy. ### The Funding and The Backers The $9.7 million round was led by BiomedVC. They were joined by other investors like NRW.Venture, Gründerfonds Ruhr, and the KHAN Technology Transfer Fund II. When you see a group like that come together, it tells you they see serious potential. Marcus Kostka, PhD, the co-founder and CEO of iDEL, put it well. He said their concept to unlock new cancer treatments represents "an exciting new opportunity with the potential to significantly impact the oncology landscape." That's the kind of bold vision that attracts this level of backing. ### A Wave of European Innovation To understand the context, look at what else is happening. iDEL's funding is part of a much larger trend. Just look at some of the other recent deals in the space: - Germany's T-CURX secured about $19.1 million for non-viral CAR-T therapies. - Switzerland's FoRx Therapeutics raised roughly $45.4 million for DNA repair-targeting treatments. - France's ErVimmune got around $18.4 million for immunotherapy. - The UK's Umlaut.bio landed a pre-Seed round for cancer and immunology programs. - Ternary Therapeutics raised about $4.4 million to use AI-designed molecular glues. Add it all up, and you're looking at over $90 million invested recently into diverse new ways to tackle cancer. It's a clear signal that investors are betting big on the next generation of oncology. ### What Makes iDEL's Approach Different? So, what's iDEL actually doing? Founded in 2025, they're tackling one of the trickiest problems in drug development: getting treatments inside cancer cells effectively. Their technology is a synthetic shuttle platform. Think of it like a specialized delivery truck that can carry different types of cargo—both large and small molecules—directly into the cell's cytosol, bypassing cellular traps. This "pan-cancer" mechanism aims for high drug exposure inside the tumor and aims to keep it there. The goal is to go after targets that have been historically "undruggable" and to make treatments more effective with fewer side effects. As Aristotelis Nastos, PhD, from lead investor BiomedVC, explained, current treatments often struggle with specificity and lasting effect. He believes iDEL's strategy can "address these limitations by improving intracellular delivery, increasing target engagement and prolonging tumor retention." ### What's Next for the Company? The new funding has a clear purpose. iDEL plans to push two of their lead programs toward clinical evaluation. They're focused on solid tumors and are building scalable value through partnerships. It's an earlier-stage effort compared to some peers, but it's squarely aimed at a fundamental challenge. The leadership team is now tasked with expanding their preclinical data and moving their most promising candidates closer to helping real patients. It's a fascinating time in biotech. When you see focused, smart science attracting this kind of capital, it gives you hope. The fight against cancer is being waged on multiple new fronts, and companies like iDEL are helping to lead the charge with some very clever engineering at the cellular level.